Ranolazine effects on angina pectoris in patients with coronary artery bridge

Phase 3

Recruiting

• Conditions: Myocardial bridge in coronary arteries.; Malformation of coronary vessels; Q24.5

• Registration Number: IRCT20230801059005N2
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

Iranian origin
No history of organ damage, heart failure or renal failure
Willingness to participate in research
Angina or dyspnea on exertion or at rest
No coronary artery disease (less than 50% stenosis in all epicardial coronary arteries)

Exclusion Criteria

Not willing to keep participating in the trial
patients younger than 18 years
Liver failure, long QT, renal failure
Using CYP3A inhibitors such as Diltiazem, Verapamil, Ketoconazole, Macrolides and protease inhibitors
Patient who are using medication that cause QT prolongation
Pregnancy or lactation
Parkinson's disease
Life expectancy less than 6 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of chest pain. Timepoint: At the beginning- 6 month later. Method of measurement: Seattle Angina Questionnaire (SAQ) and The Duke Activity Status Index (DASI).